Discovery and development of therapeutics for neurodegenerative disorders, focusing on tau pathology.
E
CSR Analysis score
The organization does not position itself on any CSR axis.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: May 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Firalis
B
Development of products and services for neuroscience and neurodegenerative disease research and diagnostics, including ELISA kits, recombinant proteins, monoclonal antibodies, and clinical samples.
UCB
A
Development and commercialization of biopharmaceutical solutions for neurological and autoimmune conditions.
AlzProtect
E
Design and development of innovative therapeutic solutions for neurodegenerative diseases, including Alzheimer's disease and tauopathies such as Progressive Supranuclear Palsy (PSP).
Initiatives identified among leaders
Engagement pour un avenir plus durable
“Engagement pour un avenir plus durable en réduisan...” - UCBMise en place d'une ligne d'intégrité pour les droits de l'homme
“UCB met en place une ligne d'intégrité pour les dr...” - UCBIntégration de la durabilité dans la stratégie de l'entreprise
“UCB a intégré la durabilité dans sa stratégie d'en...” - UCB34% of similar organizations communicate on CSR issues
+181 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports